Press Releases Immutep ADR Deutsche Boerse AG

Equities

YP1A

US45257L1089

Market Closed - Deutsche Boerse AG Other stock markets 03:50:54 2024-06-28 EDT			5-day change	1st Jan Change
1.85 ^EUR	+1.65%		-20.26%	-12.74%

06-27	ADRs End Flat; Alarum Technologies Climbs 26%	DJ
06-27	Wall Street Set to Open Marginally Lower Thursday as Investors Parse Bullish Economic Data	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Immutep Reports Positive Topline Results from TACTI-003 Phase IIb Trial in First Line Head and Neck Cancer	06-28	AQ
Immutep Limited (IMM) \| TACTI-003: the real results; Maintain Overweight A$1.13 PT (Analysts: Dr Melissa Benson and Dr Shane Storey)	06-26	PU
Immutep : Global Webcast Slides for New Efti Clinical Data in 1st Line HNSCC	06-26	PU
Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer	06-25	AQ
Immutep : successfully completes institutional placement and institutional component of entitlement offer	06-05	PU
Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial	06-02	AQ
Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024	05-15	AQ
Immutep : ESMO Breast 2024 AIPAC 003 Poster (Metastatic Breast Cancer)	05-14	PU
Positive Initial Clinical Data Reported from Immutep’s Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma	05-02	AQ
Immutep Quarterly Activities Report Q3 FY24	04-29	AQ
Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761	04-18	AQ
Wilsons - Adding Autoimmune to the indication list; Mtn Overweight, A$0.90 Tgt (Analysts: Dr Melissa Benson and Dr Shane Storey)	04-18	PU
Immutep : Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP76	04-17	PU
Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer	04-17	AQ
Immutep : Corporate Presentation	03-26	PU
Ladenburg Thalmann - Next Is Dose Optimization for BC Program; Reiterate Buy, $8.30 PT (Analyst: Ahu Demir, PhD)	03-05	PU
Wilsons - Dose it higher? Now an option; Mtn Overweight, A$0.90 Tgt (Analysts: Dr Melissa Benson and Dr Shane Storey)	03-05	PU
Immutep Announces First Clinical Data from 90mg Dosing of Efti	03-05	AQ
Immutep Quarterly Activities Report Q2 FY24	01-30	AQ
First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer	01-04	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Immutep ADR Deutsche Boerse AG

Equities

YP1A

US45257L1089

Press Releases

Filters